Acriflavine, an antibacterial agent, binds to the PAS-B subdomain of HIF1α and HIF2α thereby preventing the binding to HIF1β, an effect that results in reduced VEGF production and tumor growth (Lee et al., 2009). This evidence concerns the gene HIF1A and neoplasm.